J Côté - Concepedia

Author

J Côté

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J COTE, J Cote, J Côté, J. Cote, J. Côté, Judi Coté

Publications

411

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)

About

J Côté is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	316
2	Health Sciences	1	1	65
3	Natural Sciences	1	1	99
4	Allergy	1	1	80
5	Biochemistry	1	1	99

J Côté

Publications

387

Citations

H-Index

Page 1

	Year	Citations
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects Rajesh Krishna, AJ Bergman, Bo Jin, Clinical Pharmacology & Therapeutics High-density LipoproteinHealthy SubjectsBiochemistryPharmacological StudyMedicine	2008	99
Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study. Malo Jl, A Cartier, J Côté, American Journal of Respiratory and Critical Care Medicine AsthmaOccupational Lung DiseasesEnvironmental Lung DiseasesOccupational Health SciencesLung Inflammation	1996	80
Air in the portal vein: sonographic and Doppler manifestations. M Lafortune, B C Trinh, Peter N. Burns, Radiology VaricesVenous DiseaseHepatologyMedicinePortal Hypertension	1991	65
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production Nicholas J. Wight, Keith Gottesdiener, Nigel Garlick, Gastroenterology Cox-2 InhibitorGastrointestinal OncologyGastrointestinal PharmacologyPharmacologyGastroenterology	2001	62
Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination Rajesh Krishna, Ferdous Gheyas, Yanhong Liu, Clinical Pharmacology & Therapeutics	2017	55
Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection AW Krug, Pavan Vaddady, RA Railkar, Clinical and Translational Science	2017	16
PIII-60Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor Arthur Bergman, J Côté, Bingming Yi, Clinical Pharmacology & Therapeutics HemodialysisRenal FunctionSelective Dipeptidyl-peptidase-ivHealthy SubjectsRenal Insufficiency	2006	10

Page 1